Section Arrow
TARA.NASDAQ
- Protara Therapeutics
Quotes are at least 15-min delayed:2026/10/21 06:47 EDT
Pre Market
Last
 --
-- (--)
Bid
1.03
Ask
3.49
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 2.56
+0.23 (+9.87%)
Day High 
2.575 
Prev. Close
2.33 
1-M High
3.88 
Volume 
1.50M 
Bid
1.03
Ask
3.49
Day Low
2.33 
Open
2.34 
1-M Low
2.295 
Market Cap 
137.69M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.55 
20-SMA 2.85 
50-SMA 3.46 
52-W High 7.82 
52-W Low 2.295 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.36/-1.61
Enterprise Value
139.81M
Balance Sheet
Book Value Per Share
2.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EYPTEyePoint Inc.0.4052-0.0348-7.91%-- 
Pre Market 0.4167 +0.0115 +2.84%
RXRXRecursion Pharmaceuticals3.66+0.05+1.39%-- 
Pre Market 3.66 0 0.00%
MRNAModerna242.08+15.19+6.69%-- 
Pre Market 242.8022 +0.7222 +0.30%
IBRXImmunityBio8.77+0.35+4.16%-- 
Pre Market 8.8 +0.03 +0.34%
SLNSilence Therapeutics Plc19.61+0.03+0.15%-- 
Pre Market 19.6 -0.01 -0.05%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support,or PS, which includes both nutrition and fluids.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.